8-K: Onconetix Secures New Debt, Extends Veru Notes Amid Repayment Struggles

Onconetix, Inc. announced new promissory notes with Keystone Capital and KCP Fund I, while securing further extensions on its substantial debt obligations to Veru Inc. due to an inability to repay.

Summary

• Onconetix, Inc. (the Company) issued two new unsecured promissory notes on August 28, 2025, to Keystone Capital Partners, LLC and KCP Fund I, LLC.
• Each new note has a principal amount of $58,823.53, a purchase price of $50,000.00, and an original issue discount (OID) of $8,823.53.
• These notes are due by May 28, 2026, or earlier upon receipt of sufficient proceeds from the Company's Equity Line of Credit (ELOC) with Keystone.
• The new notes are subordinate to existing debt obligations to Veru Inc. and will incur a 15% per annum late charge if not paid when due.
• The Company also secured further extensions on its Promissory Notes with Veru Inc., originally totaling $10.0 million.
• The April Veru Note, originally due April 19, 2024, was extended to September 19, 2025.
• The September Veru Note, originally due September 30, 2024, was amended and restated twice, increasing its principal amount by $200,000 in total to $5.2 million, with a new maturity date of September 19, 2025.
• The Company explicitly stated it is "unable to repay the April 2024 Promissory Note" and is "seeking to secure financing to generate sufficient cash."

Sentiment

Score: 2

Explanation: The company is in significant financial distress, evidenced by its inability to repay existing debt, the need for constant extensions, and the high cost of new, discounted financing. While extensions provide temporary relief, they do not address the underlying liquidity issues and increase future obligations.

Positives

• Secured additional short-term financing totaling $100,000 (purchase price) from Keystone Capital Partners and KCP Fund I.
• Obtained further extensions on significant debt obligations to Veru Inc., temporarily avoiding default on the April Veru Note and the September Veru Note.

Negatives

• The Company is unable to repay the April Veru Promissory Note, indicating severe liquidity issues.
• New promissory notes from Keystone and KCP Fund I carry a significant original issue discount of 17.6% ($8,823.53 OID on a $58,823.53 principal for a $50,000 purchase price), reflecting high-cost financing.
• The September Veru Note's principal amount was increased by $200,000 in August 2025, raising the total obligation to $5.2 million.
• Repeated, short-term extensions of debt obligations to Veru Inc. (multiple times in 2025) highlight ongoing financial distress and reliance on creditor forbearance.
• The new notes include a 15% per annum late charge, indicating potentially high costs if repayment is delayed.

Risks

• Liquidity Risk: The Company explicitly states it is "unable to repay the April 2024 Promissory Note" and is "seeking to secure financing," indicating significant cash flow and liquidity challenges.
• Default Risk: Despite extensions, the Company's inability to meet prior obligations suggests a high risk of future default on the extended Veru Notes and the new Keystone/KCP notes if new financing is not secured.
• High Cost of Capital: The original issue discount on the new notes and the potential 15% late charge on new debt, along with the increased principal on the Veru note, indicate a high and increasing cost of capital.
• Reliance on Future Financing: The repayment of new notes is contingent on "sufficient proceeds from its equity line of credit" or other "subsequent offerings," making the Company highly dependent on its ability to raise future capital.
• Dilution Risk: Repayment of the new notes from "sales of any securities" (Subsequent Offering Proceeds) or the ELOC suggests potential future equity dilution for existing shareholders.
• Subordination Risk: The new Keystone/KCP notes are subordinate in right of payment to Veru Inc. debt, meaning Veru would have priority in repayment in a distress scenario.

Future Outlook

The Company is actively seeking to secure additional financing to generate sufficient cash to meet its obligations. Repayment of the newly issued notes is contingent on receiving proceeds from its equity line of credit or other future securities offerings, indicating a continued reliance on external capital.

Management Comments

• The Company is unable to repay the April 2024 Promissory Note.
• The Company is seeking to secure financing to generate sufficient cash to fulfill all applicable obligations to the Holder pursuant to the A&R Forbearance Agreement.

Industry Context

This filing reflects a company in the biotech/pharmaceutical sector (implied by "ENTADFI business" acquisition) facing significant financial distress. The repeated need for debt extensions and the issuance of high-discount, subordinate notes are characteristic of companies struggling with liquidity and access to conventional financing, often seen in early-stage or struggling life science companies with high R&D costs and uncertain revenue streams.

Comparison to Industry Standards

• The repeated, short-term debt extensions (monthly in some cases) are highly unusual for a financially healthy company and indicate a distressed financial situation, far below industry standards for stable operations.
• The original issue discount of 17.6% on the new promissory notes is a very high cost of capital, significantly exceeding typical corporate borrowing rates for established companies, even in high-growth sectors. This is comparable to distressed debt financing or bridge loans for companies with limited alternatives.
• The subordination of new debt to existing obligations (Veru Inc.) further highlights the Company's weak bargaining position and limited access to senior debt.
• The increase in the principal amount of the September Veru Note by $200,000 over a short period, alongside extensions, suggests that the Company is incurring additional costs or penalties to secure forbearance, which is not a standard practice for healthy companies.
• The reliance on an Equity Line of Credit (ELOC) and other "Subsequent Offerings" for repayment, rather than operational cash flow, is typical of early-stage or financially challenged companies that have not yet achieved profitability or sustainable revenue.

Related Party Transactions

• The new promissory notes were issued to Keystone Capital Partners, LLC and KCP Fund I, LLC, an affiliate of Keystone. Keystone also has an existing Equity Line of Credit (ELOC) with the Company.

Stakeholder Impact

• Shareholders: Potential for significant dilution if the Company raises capital through equity offerings to repay debt. The ongoing financial distress and high cost of debt could negatively impact share price.
• Creditors (Veru Inc.): Continues to provide forbearance but has increased the principal amount of one note and secured a higher percentage of future financing proceeds, indicating a cautious but accommodating stance.
• Creditors (Keystone/KCP Fund I): Provided new, high-cost, subordinate debt, indicating a willingness to provide capital but at terms reflecting the Company's risk profile.
• Employees: Financial instability could create uncertainty regarding job security or future growth prospects.
• Customers/Suppliers: No direct impact mentioned, but severe financial distress could eventually affect operational continuity.

Next Steps

• Secure additional financing to meet current and extended debt obligations.
• Repay the April Veru Note and the Second A&R September Veru Note by September 19, 2025.
• Repay the new Keystone and KCP Fund I notes by May 28, 2026, or earlier from ELOC/Subsequent Offering proceeds.

Key Dates

Recommendation

The filing reveals a company in severe financial distress, unable to meet its current debt obligations and relying on repeated, short-term extensions and high-cost, discounted new debt. The increasing principal on existing notes and the significant original issue discount on new financing indicate a deteriorating financial position and a high risk of future default or substantial equity dilution. The explicit statement of inability to repay a major note is a critical red flag for investors, suggesting significant operational and liquidity challenges that are not being sustainably addressed.

Keywords

Onconetix, ONCO, SEC Filing, 8-K, Promissory Note, Debt Extension, Forbearance Agreement, Liquidity, Capital Raise, Veru Inc., Keystone Capital Partners, KCP Fund I, Equity Line of Credit, Financial Distress, Corporate Debt, Biotech, Pharmaceutical